{
    "name": "peramivir",
    "comment": "Rx",
    "other_names": [
        "Rapivab"
    ],
    "classes": [
        "Antivirals",
        "Influenza",
        "Neuraminidase Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/rapivab-peramivir-999307",
    "pregnancy": {
        "common": [
            "Limited available data with use in pregnant women are insufficient to determine a drug- associated risk of adverse developmental outcomes; there are risks to the mother and fetus associated with influenza in pregnancy"
        ],
        "specific": [
            {
                "type": "Animal studies",
                "description": [
                    "  ",
                    "  ",
                    "Dose 8 x human recommended dose",
                    "Single IV bolus injection: No adverse effects observed",
                    "Continuous IV infusion: Reduced renal papilla and dilated ureters were observed",
                    "  ",
                    "  ",
                    "Administration of drug during organogenesis at exposures 8 times those in humans at recommended dose resulted in developmental toxicity (abortion or premature delivery) at a maternally toxic dose"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on presence of drug in human milk, effects on breastfed infant, or on milk production; drug is present in rat milk limited clinical data during lactation preclude a clear determination of risk of therapy to an infant during lactation; therefore, developmental and health benefits of breastfeeding should be considered along with motherâ€™s clinical need for therapy and any potential adverse effects on breastfed child from drug or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Known serious hypersensitivity or anaphylaxis to peramivir or any component of the product; severe allergic reactions have included anaphylaxis, erythema multiforme, and Stevens-Johnson Syndrome"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Serious skin reactions reported including erythema multiforme and Stevens-Johnson syndrome; discontinue and initiate appropriate treatment ",
                "Influenza can be associated with neurologic and behavioral symptoms including hallucinations, delirium, and abnormal behavior, in some cases resulting in fatal outcomes; postmarketing surveillance has reported delirium and abnormal behavior leading to injury in patients receiving neuraminidase inhibitors ",
                "Serious bacterial infections may begin with influenza-like symptoms or may coexist with or occur as complications during the course of influenza; peramivir has not been shown to prevent such complications "
            ],
            "specific": [
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Inactivated influenza vaccine: May administered at any time relative to use of peramivir",
                        "Live attenuated influenza vaccine (LAIV; intranasal): Antiviral drugs may inhibit viral replication and reduce vaccine efficacy; avoid LAIV within 2 weeks before or 48 hr after peramivir unless medically indicated"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "influenza virus vaccine quadrivalent, intranasal",
            "description": {
                "common": "peramivir decreases effects of influenza virus vaccine quadrivalent, intranasal by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid live attenuated influenza vaccine within 2 wk before or 48 hr after administration of neuraminidase inhibitors; inactivated influenza vaccine can be administered at any time relative to use of neuraminidase inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acyclovir",
            "description": {
                "common": "acyclovir increases levels of peramivir by decreasing renal clearance. Use Caution/Monitor. Caution when peramivir coadministered with nephrotoxic drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "adefovir",
            "description": {
                "common": "adefovir increases levels of peramivir by decreasing renal clearance. Use Caution/Monitor. Caution when peramivir coadministered with nephrotoxic drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aldesleukin",
            "description": {
                "common": "aldesleukin increases levels of peramivir by decreasing renal clearance. Use Caution/Monitor. Caution when peramivir coadministered with nephrotoxic drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amikacin",
            "description": {
                "common": "amikacin increases levels of peramivir by decreasing renal clearance. Use Caution/Monitor. Caution when peramivir coadministered with nephrotoxic drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amphotericin B deoxycholate",
            "description": {
                "common": "amphotericin B deoxycholate increases levels of peramivir by decreasing renal clearance. Use Caution/Monitor. Caution when peramivir coadministered with nephrotoxic drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carboplatin",
            "description": {
                "common": "carboplatin increases levels of peramivir by decreasing renal clearance. Use Caution/Monitor. Caution when peramivir coadministered with nephrotoxic drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cidofovir",
            "description": {
                "common": "cidofovir increases levels of peramivir by decreasing renal clearance. Use Caution/Monitor. Caution when peramivir coadministered with nephrotoxic drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cisplatin",
            "description": {
                "common": "cisplatin increases levels of peramivir by decreasing renal clearance. Use Caution/Monitor. Caution when peramivir coadministered with nephrotoxic drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clofarabine",
            "description": {
                "common": "clofarabine increases levels of peramivir by decreasing renal clearance. Use Caution/Monitor. Caution when peramivir coadministered with nephrotoxic drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "contrast media (gadolinium)",
            "description": {
                "common": "contrast media (gadolinium) increases levels of peramivir by decreasing renal clearance. Use Caution/Monitor. Caution when peramivir coadministered with nephrotoxic drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "contrast media (iodinated)",
            "description": {
                "common": "contrast media (iodinated) increases levels of peramivir by decreasing renal clearance. Use Caution/Monitor. Caution when peramivir coadministered with nephrotoxic drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flucytosine",
            "description": {
                "common": "flucytosine increases levels of peramivir by decreasing renal clearance. Use Caution/Monitor. Caution when peramivir coadministered with nephrotoxic drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "foscarnet",
            "description": {
                "common": "foscarnet increases levels of peramivir by decreasing renal clearance. Use Caution/Monitor. Caution when peramivir coadministered with nephrotoxic drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ganciclovir",
            "description": {
                "common": "ganciclovir increases levels of peramivir by decreasing renal clearance. Use Caution/Monitor. Caution when peramivir coadministered with nephrotoxic drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gentamicin",
            "description": {
                "common": "gentamicin increases levels of peramivir by decreasing renal clearance. Use Caution/Monitor. Caution when peramivir coadministered with nephrotoxic drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ifosfamide",
            "description": {
                "common": "ifosfamide increases levels of peramivir by decreasing renal clearance. Use Caution/Monitor. Caution when peramivir coadministered with nephrotoxic drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "immune globulin IV (IGIV)",
            "description": {
                "common": "immune globulin IV (IGIV) increases levels of peramivir by decreasing renal clearance. Use Caution/Monitor. Caution when peramivir coadministered with nephrotoxic drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ioversol",
            "description": {
                "common": "ioversol increases levels of peramivir by decreasing renal clearance. Use Caution/Monitor. Caution when peramivir coadministered with nephrotoxic drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "neomycin PO",
            "description": {
                "common": "neomycin PO increases levels of peramivir by decreasing renal clearance. Use Caution/Monitor. Caution when peramivir coadministered with nephrotoxic drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxaliplatin",
            "description": {
                "common": "oxaliplatin increases levels of peramivir by decreasing renal clearance. Use Caution/Monitor. Caution when peramivir coadministered with nephrotoxic drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pemetrexed",
            "description": {
                "common": "pemetrexed increases levels of peramivir by decreasing renal clearance. Use Caution/Monitor. Caution when peramivir coadministered with nephrotoxic drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "penicillamine",
            "description": {
                "common": "penicillamine increases levels of peramivir by decreasing renal clearance. Use Caution/Monitor. Caution when peramivir coadministered with nephrotoxic drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pentamidine",
            "description": {
                "common": "pentamidine increases levels of peramivir by decreasing renal clearance. Use Caution/Monitor. Caution when peramivir coadministered with nephrotoxic drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "streptomycin",
            "description": {
                "common": "streptomycin increases levels of peramivir by decreasing renal clearance. Use Caution/Monitor. Caution when peramivir coadministered with nephrotoxic drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "tacrolimus increases levels of peramivir by decreasing renal clearance. Use Caution/Monitor. Caution when peramivir coadministered with nephrotoxic drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tenofovir DF",
            "description": {
                "common": "tenofovir DF increases levels of peramivir by decreasing renal clearance. Use Caution/Monitor. Caution when peramivir coadministered with nephrotoxic drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tobramycin",
            "description": {
                "common": "tobramycin increases levels of peramivir by decreasing renal clearance. Use Caution/Monitor. Caution when peramivir coadministered with nephrotoxic drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab decreases effects of peramivir by immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vancomycin",
            "description": {
                "common": "vancomycin increases levels of peramivir by decreasing renal clearance. Use Caution/Monitor. Caution when peramivir coadministered with nephrotoxic drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zoledronic acid",
            "description": {
                "common": "zoledronic acid increases levels of peramivir by decreasing renal clearance. Use Caution/Monitor. Caution when peramivir coadministered with nephrotoxic drugs."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Diarrhea",
            "percent": "8"
        },
        {
            "name": "Neutrophils",
            "percent": "1"
        },
        {
            "name": "x",
            "percent": "109"
        },
        {
            "name": "L",
            "percent": "8"
        },
        {
            "name": "Increased serum glucose",
            "percent": "160"
        },
        {
            "name": "mg",
            "percent": "5"
        },
        {
            "name": "dL",
            "percent": "6"
        },
        {
            "name": "Creatine phosphokinase",
            "percent": "5"
        },
        {
            "name": "xULN",
            "percent": "4"
        },
        {
            "name": "Constipation",
            "percent": "3"
        },
        {
            "name": "Insomnia",
            "percent": "3"
        },
        {
            "name": "AST and ALT increased",
            "percent": "2"
        },
        {
            "name": "Hypertension",
            "percent": "3"
        },
        {
            "name": "Generally",
            "percent": "3"
        },
        {
            "name": "similar to adults",
            "percent": null
        },
        {
            "name": "except for following",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Proteinuria",
            "percent": null
        }
    ]
}